Immtech Pharmaceuticals was granted Fast Track Status from the State FDA of China for pafuramidine, an oral drug undergoing testing as a treatment for Pneumocystis pneumonia (PCP). Pafuramidine is one of the first drugs to win Fast Track Status under new, more stringent rules recently established by the SFDA. The compound was previously given both Fast Track and Orphan Drug status in the US. More details...

Stock Symbol: (AMEX: IMM)